Skip to main content
Premium Trial:

Request an Annual Quote

Barry Sleckman, Jean Amos

Premium
Barry Sleckman has become director of the division of laboratory and genomic medicine at Washington University School of Medicine in St. Louis. He is an associate professor of pathology and immunology at WUSTL. According to a statement from the university, Sleckman plans to expand the division's capabilities and research in bioinformatics and molecular and genomic testing techniques. He holds MD and PhD degrees from Harvard University and an undergraduate degree in biology from Lafayette College.
 

 
Jean Amos will become vice president of laboratory operations at Celera’s Berkeley HeartLab, starting Aug. 11. Most recently, she was senior director of genetic services at Sequenom. Prior to that, she was scientific director of human genetics at Focus Diagnostics, and before that director of molecular genetics at Specialty Laboratories. Wilson holds PhD, MS, and BS degrees in genetics from Ohio State University.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.